Literature DB >> 24373830

Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study.

J L González López1, A Arribi Vilela2, E Fernández del Palacio3, J Olivares Corral3, C Benedicto Martí3, P Herrera Portal3.   

Abstract

BACKGROUND: Catheter-related infections (CRIs) caused by peripheral intravenous catheters (PIVCs) are an increasingly common iatrogenic complication. To prevent this, recommended timelines for routine replacement of PIVCs have increased from 48 h to 72 h and subsequently to 96 h, despite a lack of supporting scientific evidence. AIM: To compare closed-system (COS) PIVCs with open-system (MOS) PIVCs.
METHODS: This prospective, randomized controlled trial compared the indwell time of COS PIVCs without complications with that of MOS PIVCs, removed only by clinical indication. In total, 1199 PIVCs (642 inpatients) were randomized and 283 PIVCs were cultured. Sixteen catheters (11 patients) were lost to the study after randomization.
FINDINGS: In total, 104,469 catheter-hours (54,173 h in 584 COS and 50,296 h in 599 MOS) were recorded. The median dwell time was 137.1h for COS PIVCs and 96 h for MOS PIVCs (P = 0.001). Among PIVCs in place for ≥ 24 h, the median dwell time was 144.5h for COS PIVCs [95% confidence interval (CI) 123.4-165.6] and 99 h for MOS PIVCs (95% CI 87.2-110.8). Use of COS PIVCs reduced phlebitis rates by 29% (31 vs 45 cases/1000 catheter-days; P = 0.004). The probability that a MOS PIVC would last for 96 h was 79.9%, and the probability that a COS PIVC would last for 144 h was 80.4%. There were no significant differences in rates of bacterial colonization per 1000 catheter-days (51.1 COS vs 54.1 MOS) or CRI (5.76 COS vs 6.65 MOS). Nevertheless, there was a 20% relative risk reduction in CRI.
CONCLUSION: Use of COS PIVCs reduced episodes of phlebitis and risk of infection at a cost of only € 0.09/day. When PIVCs are replaced based on clinical indication, COS PIVCs last for up to 144 h and MOS PIVCs last for up to 96 h without increased risk and with significant cost savings (€ 786,257/year/1000 beds).
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Catheter-related infection; Closed system; Cost analysis; Indwell time; Phlebitis; Safety peripheral intravenous catheters

Mesh:

Year:  2013        PMID: 24373830     DOI: 10.1016/j.jhin.2013.10.008

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  12 in total

1.  Improving Vascular Access Outcomes and Enhancing Practice.

Authors:  Valerie Platt; Seth Osenkarski
Journal:  J Infus Nurs       Date:  2018 Nov/Dec

2.  Complications of intravascular catheters in ICU: definitions, incidence and severity. A randomized controlled trial comparing usual transparent dressings versus new-generation dressings (the ADVANCED study).

Authors:  Silvia Calviño Günther; Carole Schwebel; Rebecca Hamidfar-Roy; Agnès Bonadona; Maxime Lugosi; Claire Ara-Somohano; Clémence Minet; Leïla Potton; Jean-Charles Cartier; Aurelien Vésin; Magalie Chautemps; Lenka Styfalova; Stephane Ruckly; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2016-10-12       Impact factor: 17.440

3.  Risk factors for peripheral venous catheter failure: A prospective cohort study of 5345 patients.

Authors:  Ya-Mei Chen; Xiao-Wen Fan; Ming-Hong Liu; Jie Wang; Yi-Qun Yang; Yu-Fang Su
Journal:  J Vasc Access       Date:  2021-05-13       Impact factor: 2.326

4.  Development of a clinical prediction rule to improve peripheral intravenous cannulae first attempt success in the emergency department and reduce post insertion failure rates: the Vascular Access Decisions in the Emergency Room (VADER) study protocol.

Authors:  Peter J Carr; James C R Rippey; Marie L Cooke; Chrianna Bharat; Kevin Murray; Niall S Higgins; Aileen Foale; Claire M Rickard
Journal:  BMJ Open       Date:  2016-02-11       Impact factor: 2.692

5.  Risk factors for complications in peripheral intravenous catheters in adults: secondary analysis of a randomized controlled trial.

Authors:  Derdried Athanasio Johann; Mitzy Tannia Reichembach Danski; Stela Adami Vayego; Dulce Aparecida Barbosa; Jolline Lind
Journal:  Rev Lat Am Enfermagem       Date:  2016-11-28

6.  Peripheral Venous Catheter-Related Adverse Events: Evaluation from a Multicentre Epidemiological Study in France (the CATHEVAL Project).

Authors:  Katiuska Miliani; Raphaël Taravella; Denis Thillard; Valérie Chauvin; Emmanuelle Martin; Stéphanie Edouard; Pascal Astagneau
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

7.  Administration of intravenous morphine for acute pain in the emergency department inflicts an economic burden in Europe.

Authors:  Montserrat Casamayor; Karen DiDonato; Marc Hennebert; Luca Brazzi; Gregor Prosen
Journal:  Drugs Context       Date:  2018-04-11

8.  Phlebitis and infiltration: vascular trauma associated with the peripheral venous catheter.

Authors:  Luciene Muniz Braga; Pedro Miguel Parreira; Anabela de Sousa Salgueiro Oliveira; Lisete Dos Santos Mendes Mónico; Cristina Arreguy-Sena; Maria Adriana Henriques
Journal:  Rev Lat Am Enfermagem       Date:  2018-05-17

9.  Incidence of and associated factors for bacterial colonization of intravenous catheters removed from dogs in response to clinical complications.

Authors:  Pedro Jose Guzmán Ramos; Cristina Fernández Pérez; Tania Ayllón Santiago; M Rosario Baquero Artigao; Gustavo Ortiz-Díez
Journal:  J Vet Intern Med       Date:  2018-03-30       Impact factor: 3.333

10.  Integrated versus nOn-integrated Peripheral inTravenous catheter. Which Is the most effective systeM for peripheral intravenoUs catheter Management? (The OPTIMUM study): a randomised controlled trial protocol.

Authors:  Maria Isabel Castillo; Emily Larsen; Marie Cooke; Nicole M Marsh; Marianne C Wallis; Julie Finucane; Peter Brown; Gabor Mihala; Peter J Carr; Joshua Byrnes; Rachel Walker; Prudence Cable; Li Zhang; Candi Sear; Gavin Jackson; Anna Rowsome; Alison Ryan; Julie C Humphries; Susan Sivyer; Kathy Flanigan; Claire M Rickard
Journal:  BMJ Open       Date:  2018-05-14       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.